Neon Therapeutics (Neon Therapeutics) Short-Term Debt & Capital Lease Obligation : $1.29 Mil (As of Mar. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Neon Therapeutics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Neon Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2020 was $1.29 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Neon Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2020 was $6.20 Mil.

Neon Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Neon Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neon Therapeutics Short-Term Debt & Capital Lease Obligation Chart

Neon Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Short-Term Debt & Capital Lease Obligation

1.24

Neon Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial									1.11	1.15	1.20	1.24	1.29

Neon Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Neon Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Neon Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Neon Therapeutics (Neon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neon Therapeutics Inc (NAS:NTGN) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Erie Street, Suite 110, Cambridge, MA, USA, 02139

Website

https://www.neontherapeutics.com

Neon Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.

Executives

Cary Pfeffer	director	C/O ELEVEN BIOTHERAPEUTICS, 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Jolie Siegel	officer: VP, General Counsel	C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Robert Kamen	director	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, BOSTON MA 02210
Meryl Zausner	director	C/O NEON THERAPEUTICS, INC., 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Yasir B. Al-wakeel	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Eric S Lander	director	415 MAIN STREET, CAMBRIDGE MA 02142
Stephen A Sherwin	director	C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Robert I Tepper	director, 10 percent owner	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Robert B Bazemore	director	33 HAYDEN AVE, LEXINGTON MA 02421
Richard Gaynor	officer: President of R&D	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Access Industries, Llc	other: Affiliate of 10% Owner	730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Management, Llc	other: Affiliate of 10% Owner	730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Holdings Llc	10 percent owner	C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Clal Biotechnology Industries Ltd.	other: See Remarks	3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik	other: Affiliate of 10% Owner	C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019